Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cardiome Oxyprim Phase IV Trial Design Will Be Part Of Chronic Gout Trial Design Cmte. Meeting

This article was originally published in The Pink Sheet Daily

Executive Summary

The Phase IV proposal will act as a case study for FDA's Arthritis Advisory Committee's discussion June 2. The study will fulfill accelerated approval requirements for oxypurinol, which has a June 23 user fee date. The committee will also look at acute gout; Merck's Arcoxia will be discussed.

You may also be interested in...

Cardiome Oxyprim, Chronic Gout Drug Trials May Use Surrogate Endpoints For Approval, Cmte. Says

Surrogate endpoint should seek a reduction in serum uric acid to a level of 6 mg/dL. Clinical outcome trials to confirm benefits of chronic gout products through reduction in gouty attacks should be carried out post-approval.

Pandemic Perspectives: What’s The New Normal For The Business Of Biopharma?

In Part 2 of Scrip’s roundtable, execs from Athira, Cartesian, Cyclacel, Tonix and VOZ Advisors discuss how the pandemic brought in new investors and triggered strategic shifts for the biopharma industry. 





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts